Introduction
Benzodiazepines (BDZ) are the most widely used drugs for anxiety because of their anxiolytic and hypnotic effects. Some variants also have anticonvulsant and muscle relaxant activity. 1 Because of their multiple uses, BDZ are among the most prescribed drugs in the world and are taken by about 4% of the population. 2 In Brazil, BDZ are also among the most commonly used drug classes, according to the II Home Survey on the use of psychotropic drugs in Brazil (2005) . This survey was conducted with 7,939 respondents in 108
Brazilian cities with more than 200,000 inhabitants and 5.6% of respondents reported BDZ use. 3 Consumption of BDZ is becoming a public health problem because of often indiscriminate use. 4 Another factor that may favor increased use of BDZ is free distribution by the public health system, since this makes them accessible to a large population, and is associated with a lack of protocols to guide prescribing and dispensing. 5 Benzodiazepines have a high potential for addiction, 6 which is related to their pharmacokinetics. 7 The higher the lipid solubility and lower the half-life, the greater the potential for drug dependence, and since lipid solubility is what determines the absorption rate and the speed and extent of drug delivery, it is an important feature of BDZ, which have good tissue distribution and cross the blood-brain barrier easily. 8 Furthermore, these drugs can cause tolerance and other adverse events, increasing the risk of morbidity and mortality and raising health care costs. 9 Although BDZ are safer than other classes of drugs used for the same therapeutic purposes, their use must be monitored due to the high incidence of side effects 10 including drowsiness, confusion, impaired psychomotor activity, memory impairment, tolerance and dependence, in addition to potentiation of the depressant effect by interaction with other depressant drugs, such as alcohol. of whom acquired their medicines by prescription.
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However, no studies have been carried out in Brazil to assess anxiety in BDZ users, which is a differentiating factor in the present study's approach.
In view of the lack of studies assessing dependence and anxiety among users of BDZ and their risks, this study aims to determine levels of dependence and anxiety among continuous users of these drugs on the public health system and the indications for their prescription.
Method
This is a cross-sectional, descriptive and quantitative study, which was conducted in two stages:
1) The dispensing pharmacy at the Saldanha Marinho municipal health center maintains a database of the drugs it dispenses. In December 2014, this database was queried to identify users to whom BDZ were dispensed between January and August 2014, and select those who had received at least three dispensations during this period.
2) All users selected were visited. Data collection was 
Results
The sample comprised 42 BDZ users, 76.2% of whom were female, as shown in Table 1 .
The BDZ presentations dispensed at the community health center were as follows: a) clonazepam pharmaceutical oral solution (2.5 mg/mL) or pills (2 mg); b) diazepam pills (5 mg and 10 mg). The most common BDZ presentation used in this study was 2.5 mg clonazepam/mL (52.4%), followed by diazepam 10 mg, prescribed to 33.3% ( Table 2 ).
As shown in Table 3 , none of the users reported using BDZ for a period of less than 1 year. Most (61.9%) had been taking them for 1 to 5 years and the mean duration was 6.5 years (± 6.47). The most often cited first prescriber was a general practitioner (76.2%), followed by a neurologist (11.9%). The most frequent indications were insomnia (71.4%) and anxiety (28.6%).
The results of the Hamilton Anxiety Scale assessments demonstrated that most patients had a severe degree of anxiety (47.66%), followed by moderate (26.2%) and mild anxiety (19.04%) ( Table 4 ).
The most frequently reported diseases were hypertension (69%), depression (31%) and diabetes (12%). Notwithstanding, 60% of the patients reported taking antidepressants and the most commonly used classes were selective serotonin reuptake inhibitors with 56%, followed by nonselective monoamine oxidase inhibitors with 40%. However, many users may ignore the risk of dose increase since its pharmaceutical form is oral solution, considering them safer than pills, and guidance on this matter is the responsibility of health professionals. It is also noteworthy that both drugs are on both the REMUME and the National List of Essential Medicines (RENAME).
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The first prescriber for most users was their general practitioner, as was reported in another study, 17 in which 80% of BDZ prescriptions were made by general practitioners. However, these professionals often do not feel comfortable dealing with mental illness and report difficulties. 30 The lack of psychiatrists at primary care health centers could be one reason why most prescriptions are written by general practitioners. One of the functions of primary care is to resolve cases and small problems should be solved at the health center level and only when necessary should cases be referred to specialized care. 31 Specialized care within the SUS for patients with mental health problems is provided by Centers for Psychosocial Care (CAPS), which offer various services such as psychotherapy, drug counseling and social support group activities. 32 However, this service is not available in the city studied, and referral to a different municipality is required.
The main indication for taking BDZ was insomnia, followed by anxiety. These findings are consistent with
The age group containing most BDZ users was the over 60s (47.6%), followed by the 46-59 years range (40.5%), and the mean age of the sample was 60.7 ± 13.6 years. The great majority of the sample reported that they had not completed primary education (73.8%).
The most frequent marital status category was married, at 47.6%, and 78.6% of users reported that they did not live alone (Table 1) .
Drug dependence was assessed using the Benzodiazepine Dependence Self-Report Questionnaire.
As shown in Table 5 , 61.9% of users were considered dependent and according to the dichotomized scores problematic use ratings were moderate for most users (42.9%), Preoccupation was very high for 78.6% (33) of users and the lack of compliance was moderate for 20 (47.6%) users and high for 13 (31%).
There were a total of 42 respondents and 50% (21) of them had attempted to stop taking BDZ. Within this subset, 57.1% (12) had had problems related to withdrawal of BDZ, with very high scores for the withdrawal subscale. Additionally, none of the users interviewed reported successfully withdrawing BDZ.
Discussion
There was a higher percentage of women than men among the BDZ users, which has also been demonstrated in several other studies. [15] [16] [17] [18] The greater frequency of BDZ use by women may be related to their higher prevalence of depression and anxiety. 19 Additionally, women are less resistant to using medication, recognize disease symptoms, are more concerned with their health and more often seek health services than men.
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The predominant age group was elderly (≥ 60 years), in common with the results of a study 18 10 However, it is noteworthy that these drugs are not listed on the Municipal Register of Essential Medicines (REMUME) in the municipality
The BDZ users were also assessed for degree of anxiety using the Hamilton Anxiety Scale 12 and most had a severe degree of anxiety, despite taking BDZ. This can be explained by development of tolerance, since the users in this study had prolonged duration of use of these drugs.
In contrast, a Spanish study 39 Tolerance is the first observable result of chronic BDZ use. 8 It is characterized by a decrease in pharmacological response and is possibly related to changes in relation to the receptors of these drugs. 40 Repeated administration of the drug causes a shift of the dose-response curve to the right, so that higher doses/concentration of the drug are needed to produce the same effect, thus increasing the risk of BDZ users taking doses greater than those prescribed by their doctors. 41 It is important to clarify that tolerance and withdrawal symptoms occur by reversible physiological adaptations to exposure to drugs and do not imply dependence, since it is known that people can exhibit dependence with no withdrawal symptoms and suffer withdrawal without being dependent. 8 Most respondents reported taking antidepressants, but a smaller number reported having depression.
However, in severe cases of anxiety, physicians often prescribe an antidepressant in conjunction with the BDZ, 10 because many drugs used to treat depression also have an anxiolytic effect, including selective serotonin reuptake inhibitors, which was the class most used in combination with BDZ in another study, because they also treat the symptoms of anxiety. 42 Non-selective monoamine oxidase inhibitors were the second most used class of antidepressants, which may be related to their sedative effect, making them useful for the treatment of depression mixed with anxiety. 10 Additionally, another common indication for using antidepressants with BDZ is major depression. A multicenter study 43 conducted in Japan found that approximately 60% of patients who consulted a psychiatrist for the first time for major depression were prescribed a BDZ in addition to an antidepressant. In the United States, one in three patients who were on pharmacological treatment with antidepressants used an anxiolytic simultaneously. 43 Concomitant use of an anxiolytic antidepressant in initial therapy is often necessary because the acute depression phase is accompanied by irritability, anxiety descriptions in the literature and they are the main clinical uses of BDZ in psychiatry and general medical practice. 1, 10 Note that insomnia is a symptom and not a disease, its association with anxiety is common and both are treated together with BDZ. 10 The duration of BDZ use was greater than 1 year for all respondents in this study, with a long mean duration of use. One study 33 Given these risks, it is considered that the ideal treatment period is less than 6 months, which may decrease the risk of dependence and tolerance. As mentioned, all BDZ users in this study were taking them for more than six months and are potentially subject to tolerance and dependence, factors that were also assessed in this study.
The assessment of dependence on BDZ found that more than half of users did not meet the criteria for dependence on BDZ. Another study, 37 between the present study and the others could be that the first one employed a different methodology for dependency assessment and that the high dependency rate in the present study could be related to the inclusion criteria of using BDZ for at least three months, since dependence can occur rapidly, after 4 to 6 weeks' use, and after 3 months of continuous use it affects the majority of patients.
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A study 38 conducted in Nijmegen, in the Netherlands, examined 599 outpatient users of BDZ with the Benzodiazepine Dependence Self-Report Questionnaire, 13 for which evaluation is based on mean scores and reported high levels of problematic use, and of problems related to withdrawal of BDZ, while lack of compliance was considered low, i.e., patients adhered to the treatment.
In the present study, most users had moderate scores for problematic use, scores for preoccupation were very high and lack of compliance scores were moderate. and insomnia. Furthermore, the onset of antidepressant effect is slow, and there may be a worsening of depressive symptoms in the early days. 44 Therefore, BDZ can be used concurrently for the first week, during the antidepressant latency period. 45 With regard to attempts to interrupt use of BDZ, 50%
reported discontinuing use of the BDZ, which somewhat indicates knowledge about the consequences of prolonged use of these drugs. However, there was a high rate of problems, with patients feeling depressed, tired, upset, angry and restless and none of them succeeded. The most frequent problems with withdrawal of BDZ involve three types of syndromes: recurrence, in which the symptoms of the disease return, rebound, which is characterized by a return of the symptoms of the disease at a higher intensity, and withdrawal, in which new symptoms appear that can range from tremors, nausea, vomiting, anxiety and irritability to tonic-clonic seizures and hallucinations. 8 Gradual withdrawal of BDZ is therefore recommended, even in patients on therapeutic doses, to relieve symptoms such as those mentioned above. 46 Inappropriate use of BDZ is becoming a cause for concern and it is necessary to rationalize excessive use of these drugs, which over time have been growing into a public health problem. When indicated, prescriptions must be set within the lower therapeutic doses and for the shortest time possible, not exceeding 6 months of treatment. 47 Furthermore, health professionals should be advised to inform patients about the consequences for their quality of life of incorrect BDZ use, and to take precautions that minimize the complications arising from the use of these drugs.
17

Conclusion
This study has highlighted prolonged and inappropriate use of BDZ, which is becoming a public health problem.
Furthermore, the growth in consumption of BDZ demonstrates a need to raise awareness about rational use of these drugs among the public and among the professionals involved.
Primary care health centers should run support groups for these patients, which would encourage reduced usage of BDZ and should encourage participation in nonpharmacological measures such as mental health groups, consultations with psychologists and alternative therapies, to thereby reduce use of these drugs and the problems related to them, such as dependence and tolerance.
There is a need for debate on the problems reported in this study, to seek strategies to address them.
